Alkermes plc (NASDAQ:ALKS) reported fourth-quarter results on Wednesday that surpassed revenue expectations but fell short on earnings, with shares climbing more than 3% in after-hours trading as investors focused on sales momentum and forward guidance.
The biopharmaceutical company generated quarterly revenue of $384.5 million, slightly ahead of the consensus estimate of $383.07 million.
Adjusted earnings per share came in at $0.29, however, missing analyst expectations of $0.41 by $0.12.
Alkermes issued fiscal 2026 revenue guidance ranging from $1.73 billion to $1.84 billion. The midpoint of $1.785 billion sits just below the analyst consensus forecast of $1.83 billion.
The company develops and markets neuroscience-focused therapies, with approved treatments addressing alcohol and opioid dependence, schizophrenia, bipolar I disorder and narcolepsy.
Alkermes recently completed the acquisition of Avadel Pharmaceuticals, adding the FDA-approved sleep medicine LUMRYZ to its commercial portfolio and accelerating its expansion into the sleep disorder treatment market.
Headquartered in Dublin, the company also operates a corporate office and research and development hub in Massachusetts, along with a manufacturing facility in Ohio.
Its development pipeline includes late-stage clinical programs targeting narcolepsy and idiopathic hypersomnia, as well as early-stage orexin 2 receptor agonists being studied for additional neurological conditions.